These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 32675703)

  • 1. Incidence and Risk Factors of Recurrent Clostridioides difficile Infection in Patients With Cirrhosis.
    Phatharacharukul P; Purpura RD; Gandhi D; Xu H; Bickett-Burkhart K; Chalasani N; Fischer M; Orman ES
    Clin Transl Gastroenterol; 2020 Jul; 11(7):e00189. PubMed ID: 32675703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.
    Stabholz Y; Paul M
    Clin Microbiol Infect; 2024 Jan; 30(1):51-58. PubMed ID: 37690610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.
    Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM
    J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
    Gentry CA; Campbell DL; Williams RJ
    Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.
    Kurti Z; Lovasz BD; Mandel MD; Csima Z; Golovics PA; Csako BD; Mohas A; Gönczi L; Gecse KB; Kiss LS; Szathmari M; Lakatos PL
    World J Gastroenterol; 2015 Jun; 21(21):6728-35. PubMed ID: 26074711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and outcomes of Clostridium difficile infection in hospitalized patients.
    Lee HY; Hsiao HL; Chia CY; Cheng CW; Tsai TC; Deng ST; Chen CL; Chiu CH
    Biomed J; 2019 Apr; 42(2):99-106. PubMed ID: 31130254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.
    Lee CC; Lee JC; Chiu CW; Tsai PJ; Ko WC; Hung YP
    Microbiol Spectr; 2021 Oct; 9(2):e0079921. PubMed ID: 34668727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clostridioides difficile infection in immunocompromised hospitalized patients is associated with a high recurrence rate.
    Avni T; Babitch T; Ben-Zvi H; Hijazi R; Ayada G; Atamna A; Bishara J
    Int J Infect Dis; 2020 Jan; 90():237-242. PubMed ID: 31672656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials.
    Igarashi Y; Tashiro S; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
    J Infect Chemother; 2018 Nov; 24(11):907-914. PubMed ID: 30170735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Readmission Predicts Increased Mortality in Cirrhosis Patients After Clostridium difficile Infection.
    Kruger AJ; Durkin C; Mumtaz K; Hinton A; Krishna SG
    J Clin Gastroenterol; 2019 Sep; 53(8):e322-e327. PubMed ID: 30045168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, outcome, and risk factors for recurrence of nosocomial Clostridioides difficile infection in adults: A prospective cohort study.
    Karaoui WR; Rustam LBO; Bou Daher H; Rimmani HH; Rasheed SS; Matar GM; Mahfouz R; Araj GF; Zahreddine N; Kanj SS; Berger FK; Gärtner B; El Sabbagh R; Sharara AI
    J Infect Public Health; 2020 Apr; 13(4):485-490. PubMed ID: 31838001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clostridioides (Clostridium) difficile infection in Japanese hospitals 2008-2017: A real-world nationwide analysis of treatment pattern, incidence and testing density.
    Kimura T; Stanhope S; Sugitani T
    J Infect Chemother; 2020 May; 26(5):438-443. PubMed ID: 32081648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is advanced age still a risk factor for recurrence of C. difficile infection in the era of new treatments?
    Suárez-Carantoña C; Corbacho-Loarte MD; Del Campo Albendea L; Kamel-Rey S; Halperin AV; Escudero-Sánchez R; Ponce-Alonso M; Moreno S; Cobo J
    Age Ageing; 2024 Aug; 53(8):. PubMed ID: 39141079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Is the Role for Metronidazole in the Treatment of Clostridium difficile Infection? Results From a National Cohort Study of Veterans With Initial Mild Disease.
    Appaneal HJ; Caffrey AR; LaPlante KL
    Clin Infect Dis; 2019 Sep; 69(8):1288-1295. PubMed ID: 30561531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
    Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
    Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.
    Bouza E; Alcalá L; Marín M; Valerio M; Reigadas E; Muñoz P; González-Del Vecchio M; de Egea V
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1777-1786. PubMed ID: 28501926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.